A New Clinical Pathway for Patients With Fractured Neck of Femur
Launched by NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY · Apr 25, 2008
Trial Information
Current as of June 12, 2025
Completed
Keywords
ClinConnect Summary
The intention of the present project is to evaluate the effectiveness of multi-factorial medical treatment of patients with hip fractures in a specially designed geriatric unit for elderly hip fracture patients (orthogeriatric unit) as compared to traditional care in an orthopedic unit.
Every year 9000 patients undergo surgery for hip fractures in Norway. The epidemic of hip fractures is among the most common causes of acute hospitalization of older people and is associated with high morbidity, mortality, disability and subsequent hospital and social costs as well as reduction in quality o...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age \>70 years
- • living in nearby municipalities
- • able to walk 10 m before fracture
- • medial, pertrochanteric and subtrochanteric hip-fractures
- Exclusion Criteria:
- • nursing home residents
- • expected to die within 3 months
- • pathological fractures
About Norwegian University Of Science And Technology
The Norwegian University of Science and Technology (NTNU) is a leading research institution dedicated to advancing knowledge and innovation in various scientific fields. Renowned for its commitment to interdisciplinary collaboration, NTNU plays a pivotal role in addressing global health challenges through rigorous clinical trials and research initiatives. The university's emphasis on cutting-edge technology and its strong partnerships with healthcare sectors position it as a key player in translational research, ensuring that findings contribute effectively to improving public health and patient care. With a focus on ethical standards and scientific integrity, NTNU is dedicated to fostering advancements that enhance the quality of life and health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Olav Sletvold, MD. Ph D
Principal Investigator
Department of Neuroscience, Norwegian University of Science and Technology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials